Abstract
Purpose
To compare oocyte cryopreservation cycles performed in cancer patients to those of infertile women.
Methods
Cancer patients referred for fertility preservation underwent counseling in compliance with the ASRM; those electing oocyte cryopreservation were included. Ovarian stimulation was achieved with injectable gonadotropins and freezing was performed using slow-cooling and vitrification methods.
Results
Fifty cancer patients (mean age 31 y) underwent oocyte cryopreservation; adequate ovarian stimulation was achieved in 10 ± 0.3 days. The outcome from these cycles included a mean peak estradiol of 2,376 pg/ml and an average of 19 oocytes retrieved (15 mature oocytes were cryopreserved/cycle). All patients tolerated ovarian hyperstimulation. There were no significant differences noted between cryopreservation cycles performed in cancer patients and in women without malignancy.
Conclusions
Oocyte cryopreservation appears to be a feasible fertility preservation method for reproductive-age women diagnosed with cancer. This modality is not only effective but also, providing a multidiscipline effort, can be completed in timely fashion.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics. CA Cancer J Clin. 2009;59:225–49.
Surveillance, Epidemiology and End Results data. http://seer.cancer.gov/statfacts/html/all.html. Accessed March 4, 2009.
Knopman JM, Papadopoulos E, Grifo J, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 15 Feb 2010. doi:10.1016/S1470-2045(09)70317-1, [Epup ahead of print].
American Society of Reproducitve Medicine. Practice Committee response to Rybak and Lieman: elective self-donation of oocytes. Fertil Steril. 2009;92:1513–4.
Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Essential elements of informed consent for elective oocyte cryopreservation: a practice committee opinion. Fertil Steril. 2008;90:S134–5.
Noyes N, Knopman J, Labella P, McCaffrey C, Clark-Williams M, Grifo J. Oocyte cryopreservation outcomes including pre-cryo and post-thaw meiotic spindle evaluation following slow cooling and vitrification of human oocytes. Fertil Steril. 26 Feb 2010. doi:10.1016/j.fertnstert.2010.01.019, [Epub ahead of print].
Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010;93:609–15.
Carrell D, Kuneck P, Peterson C, Hatasaka H, Jones K, Campbell B. A randomized prospective analysis of five sperm preparation techniques before intrauterine insemination of husband sperm. Fertil Steril. 1998;69:122–6.
Cobo A, Kuwayama M, Perez S, Ruiz A, Pellicer A, Remohi J. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the CryoTop method. Fertil Steril. 2008;89:1657–64.
Nagy ZP, Chang CC, Shapiro DB, Bernal DP, Elsner CW, Mitchell-Leef D, et al. Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. Fertil Steril. 2009;92:520–6.
Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common development disorder with environmental aspects. Hum Reprod. 2001;16:972–8.
Magelseen H, Brydoy M, Fossa SD. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract. 2006;3:312–22.
Pal L, Leykin L, Schifren J, Isaacson K, Chang YC, Nikruil N, et al. Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod. 1998;13:1837–40.
Knopman J, Noyes N, Talebian S, Krey L, Grifo J, Licciardi F. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril. 2009;9:1476–8.
Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91.
Porcu E, Venturoli S, Damiano G, Ciotti PM, Notarangelo L, Paradisi R, et al. Healthy twins delivered after oocyte cryopreservation and bilateral ovariectomy for ovarian cancer. Reprod Biomed Online. 2008;17:267–9.
Acknowledgments
The authors would like to thank the entire IVF team at the NYUFC for their efforts and participation in the oocyte cryopreservation program and all the oncologists who referred patients for fertility preservation treatment. Dr. Noyes would also like to thank Dr. Eleonora Porcu of Bologna, Italy for introducing her to oocyte cryopreservation technology and its application as a fertility preservation measure in cancer patients.
Financial Support
Schering Plough provided fertility medication for some of the non-cancer patients.
Conflicts of Interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Capsule Oocyte cryopreservation has become increasingly successful, offering female cancer patients a viable means to preserve their fertility.
Rights and permissions
About this article
Cite this article
Noyes, N., Labella, P.A., Grifo, J. et al. Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. J Assist Reprod Genet 27, 495–499 (2010). https://doi.org/10.1007/s10815-010-9434-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-010-9434-3